Petros Grivas MD, PhD

Dr. Grivas on the Role of Targeted Therapy in Prostate Cancer

March 27th 2020

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

Dr. Grivas on PARP inhibition in Germline and DNA Damage Repair-Mutated mCRPC

March 18th 2020

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC

March 7th 2020

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Grivas on Investigational Immunotherapy Approaches in Localized Bladder Cancer

May 4th 2019

Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program and associate professor, Department of Medicine, Division of Oncology, University of Washington, and medical oncologist, Seattle Cancer Care Alliance, discusses investigational immunotherapy approaches in localized bladder cancer.

Dr. Grivas on Immunotherapy in Platinum-Refractory Metastatic Bladder Cancer

March 19th 2019

Petros Grivas, MD, PhD, director of Genitourinary Cancers Program and associate professor of Oncology, University of Washington, medical oncologist, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with metastatic platinum-refractory bladder cancer.

Dr. Grivas on Bladder Preservation in Localized Bladder Cancer

March 9th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses data on bladder preservation in patients with localized bladder cancer.

Dr. Grivas on Unmet Needs in Advanced Urothelial Cancer

February 20th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses unmet needs in the treatment of patients with advanced urothelial cancer.

Dr. Grivas on Checkpoint Inhibitors in Localized Bladder Cancer

February 7th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the role of checkpoint inhibitors in the treatment of patients with localized bladder cancer.

Dr. Grivas on Promising Combination Therapies in Bladder Cancer

January 19th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.

Checkpoint Inhibitors Herald New Era in Urothelial Cancer

January 9th 2019

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

Dr. Grivas on Mechanisms of Immune Response in Bladder Cancer

December 18th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.

Dr. Grivas on Combination Strategies in Genitourinary Cancer

September 13th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination strategies in genitourinary cancer.

Dr. Grivas on the IMvigor211 Trial in Metastatic Urothelial Carcinoma

August 8th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.

Dr. Grivas on Ongoing Trials in Advanced Bladder Cancer

July 7th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses ongoing trials in advanced bladder cancer.

Dr. Grivas on Immunotherapy in Advanced Urothelial Cancer

June 19th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with advanced urothelial cancer.

Dr. Grivas on Emerging Biomarkers in Urothelial Cancer

June 5th 2018

Petros Grivas MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program , associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses emerging biomarkers in advanced urothelial cancer.

Dr. Grivas on the Next Steps for Immunotherapy in Bladder Cancer

December 7th 2017

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses next steps for immunotherapy for the treatment of patients with bladder cancer.

Dr. Grivas on Combining Chemotherapy and Immunotherapy in Bladder Cancer

November 14th 2017

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses combining chemotherapy and immunotherapy as a treatment approach for patients with bladder cancer.